New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 27, 2014
10:00 EDTMHK, MTG, ETFC, SMI, XOOM, POT, MTH, HON, ATLS, HAFC, SALE, BTU, MRK, EIX, AGI, KSU, FMBI, PBOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Alamos Gold (AGI) upgraded to Outperform from Sector Perform at RBC Capital... Atlas Energy (ATLS) upgraded to Outperform from Neutral at RW Baird... E-Trade (ETFC) upgraded to Outperform from Market Perform at JMP Securities... Edison International (EIX) upgraded to Hold from Underperform at Jefferies... Honeywell (HON) upgraded to Buy from Hold at Lagenberg... MGIC Investment (MTG) upgraded to Outperform from Market Perform at JMP Securities... Merck (MRK) upgraded to Overweight from Underweight at Morgan Stanley... Meritage Homes (MTH) upgraded to Overweight from Equal Weight at Barclays... Mohawk (MHK) upgraded to Overweight from Neutral at JPMorgan... Peabody (BTU) upgraded to Neutral from Underperform at BofA/Merrill... Potash (POT) upgraded to Outperform from Market Perform at Raymond James... Prosperity Bancshares (PB) upgraded to Outperform from Market Perform at BMO Capital... RetailMeNot (SALE) upgraded to Buy from Neutral at Goldman... Xoom (XOOM) upgraded to Strong Buy from Market Perform at Raymond James... First Midwest (FMBI) upgraded to Outperform from Market Perform at Fig Partners... Hanmi Financial (HAFC) upgraded to Outperform from Market Perform at Keefe Bruyette... Semiconductor Manufacturing (SMI) upgraded to Buy from Sell at UBS... Kansas City Southern (KSU) upgraded to Neutral from Underperform at Buckingham.
News For AGI;ATLS;ETFC;EIX;HON;MTG;MRK;MTH;MHK;BTU;POT;PB;SALE;XOOM;FMBI;HAFC;SMI;KSU From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
November 11, 2014
09:37 EDTMRKActive equity options trading
Subscribe for More Information
08:10 EDTMRKMerck reports results from Phase 2 study of Grazoprevir/Elbasvir
Subscribe for More Information
November 10, 2014
17:29 EDTXOOMAncient Art, L.P. reports 5.7% stake in Xoom
Subscribe for More Information
15:51 EDTPOTMorgan Stanley to hold a conference
Subscribe for More Information
14:29 EDTPOTCapital World Investors reports 10.0% passive stake in Potash
Subscribe for More Information
13:46 EDTSALEZhengxu He reports 7.61% passive stake in RetailMeNot
Subscribe for More Information
12:07 EDTPOTUSDA lowers corn production forecast by 68M bushels
Subscribe for More Information
10:18 EDTSALERetailMeNot rises after Scopia Capital reports 13.74% passive stake
Subscribe for More Information
10:17 EDTSALEOptions with decreasing implied volatility
Options with decreasing implied volatility: RMTI ACHN RPRX ARCP SALE ZU KING UBNT KATE AWAY
10:07 EDTSALEScopia Capital reports 13.74% passive stake in RetailMeNot
09:54 EDTSALEScopia Capital reports 11.74% passive stake in RetailMeNot
Subscribe for More Information
09:20 EDTMRKOn The Fly: Pre-market Movers
Subscribe for More Information
08:48 EDTMRKGilead rises after Merck presents data on HCV combo
Subscribe for More Information
07:20 EDTMRKGilead overhang from Merck HCV combo removed, says Wells Fargo
Subscribe for More Information
07:02 EDTMTGMGIC Investment reports October primary new insurance written $3.3B
Reports beginning primary delinquent inventory of 83,154 loans and ending primary delinquent inventory of 82.,369 loans.
05:45 EDTHONHoneywell to boost refinery operations in Turkey
Subscribe for More Information
November 9, 2014
18:58 EDTMRKMerck presents interim data from C-SWIFT study
Merck announced the presentation of interim data from the C-SWIFT study exploring the potential of a candidate triple-therapy regimen consisting of the fixed-dose combination of grazoprevir/elbasvir , the company’s investigational NS3/4A protease inhibitor and NS5A inhibitor, in combination with sofosbuvir, a nucleotide inhibitor for the treatment of chronic hepatitis C virus, HCV, infection. Preliminary findings in treatment-naïve HCV genotype 1- infected non-cirrhotic patients, following six and four weeks of treatment, and patients with cirrhotic disease, following eight and six weeks of treatment, will be presented by Dr. Eric Lawitz, vice president, scientific and research development, The Texas Liver Institute, San Antonio, TX and C-SWIFT lead investigator. This poster presentation is part of a late-breaking abstract session at the 65th American Association for the Study of Liver Diseases, AASLD, Annual Meeting, also known as The Liver Meeting. “These interim data provide a compelling proof-of-concept for the potential of an eight- or six-week triple therapy course in treatment-naive patients with genotype 1 disease, including cirrhotic patients,” said Dr. Lawitz. “These findings will inform the design of larger studies aimed at understanding the potential of short-duration triple therapy across multiple patient types.”
November 7, 2014
10:40 EDTSALEOptions with decreasing implied volatility
Subscribe for More Information
10:11 EDTHONHigh option volume stocks
High option volume stocks: CTIC AVG RMTI XLY OLED HON GNW ADP PAYX MDRX
05:54 EDTHAFCHanmi Financial reports Q3 EPS 41c, consensus 33c
Subscribe for More Information
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use